The acquisition would expand Medtronic’s offerings in orthopedic surgery and complement the company’s existing presence in spine, neurosurgery, neuromodulation, advanced energy and surgical navigation. The total value of the transaction, net of Kanghui’s cash, is expected to be approximately $755 million.
More Articles on Orthopedic Devices:
Amedica Receives FDA Approval for Interbody Fusion Device
Smith & Nephew Devices Approved For Additional Indications
Alphatec Spine to Acquire Some Assets of Phygen
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.